Provided by Tiger Fintech (Singapore) Pte. Ltd.

IX Biopharma

0.020
0.000
Volume:73.90K
Turnover:1.41K
Market Cap:17.76M
PE:-1.72
High:0.020
Open:0.018
Low:0.018
Close:0.020
52wk High:0.029
52wk Low:0.015
Shares:887.96M
Float Shares:478.30M
Volume Ratio:0.30
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.012
EPS(LYR):-0.012
ROE:-431.07%
ROA:-30.32%
PB:48.66
PE(LYR):-1.73

Loading ...

Company Profile

Company Name:
IX Biopharma
Exchange:
SGX
Establishment Date:
2004
Employees:
42
Office Location:
No. 14-01 Great World City East Lobby,1 Kim Seng Promenade,Singapore,Singapore
Zip Code:
237994
Fax:
65 6235 2170
Introduction:
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.